The European Patent Office (EPO) has published patent application EP2026030729A1, titled "USE OF A RXR AGONIST IN TREATING CANCER." This publication, dated March 18, 2026, details the use of a specific class of compounds (RXR agonists) for therapeutic applications, particularly in cancer treatment. The application includes various International Patent Classification (IPC) codes related to pharmaceutical compositions, drug manufacturing, and medical treatment.

This patent publication is primarily an informational disclosure of an invention. It does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in cancer research and drug development, as it pertains to intellectual property within this therapeutic area. The designation of inventors has not yet been filed, and the application is designated for several European countries.